U.S. experts and other publications claim that ordinary people do not need to receive the third dose of new crown vaccine
China News Service, September 14th. According to Kyodo News Agency of Japan, two officials from the U.S. Food and Drug Administration (FDA) and a team of experts from the World Health Organization (WHO) were published in the British medical journal The Lancet on the 13th. An article published on the article stated that there is no data or evidence to show that ordinary people need to receive a third dose of the new crown vaccine. The reason is that existing vaccines have sufficient anti-severe effects against mutant viruses including delta strains.
p > On January 4, 2021 local time, New York, USA, nurse Sandra Lindsay received the second shot of the new crown virus vaccine at the Long Island Jewish Hospital.
U.S. media previously reported that the two FDA resigned because they opposed the US President Biden’s policy of vaccinating ordinary adults with the third dose of vaccine before the FDA review. The article believes that under the current vaccine supply, widespread vaccination for unvaccinated populations such as developing countries can save more lives than advancing the third dose.
The team collected and analyzed global reports on vaccine effectiveness mainly from European and American manufacturers. The article pointed out that for the delta strain, although the infection rate increased after inoculation compared to the alpha strain originating from the United Kingdom, the effect of preventing severe illness and hospitalization was at a higher level. Even if antibodies decrease over time, other defense methods of immune cells will come into play, and the effect of preventing severe disease will not be immediately weakened.
At present, some countries such as Israel have begun to inoculate the third dose. The WHO has called on countries not to receive the third dose during the year in order to supply vaccines to developing countries.
The U.S. government plans to give the third dose to people over 18 years of age who have received the second dose in the past 8 months from the 20th. On the 17th before this, the FDA’s external expert committee will discuss whether this move is appropriate. The FDA currently approves the third dose for specific populations with low immunity.